59 results about "Cervical intraepithelial neoplasia" patented technology

Methods for treating, preventing, controlling the growth of and/or reducing the risk of developing cervical cancer, particularly in patients with cervical intraepithelial neoplasia are provided employing pharmaceutically acceptable preparations of DFMO. Methods for treating a patient having cervical intraepithelial neoplasia, which methods comprise administering DFMO alone or in combination with a cytotoxic or cytostatic agent, are also provided.

A method for differentiating cancerous lesions from surrounding tissue, which includes extracting an opacity parameter from acetowhite regions of pre acetic acid and post acetic acid images of a cervix.

The invention relates to non-surgical methods for treating cervical or vaginal neoplasia including cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia and ano-genital warts. The treatment, which utilizes an effective amount of indole-3-carbinol and/or diindolylmethane, is effective whether or not the patient is also infected with human papillomavirus, the most common sexually transmitted viral disease in the United States and a known risk factor for both cervical intraepithelial neoplasia and cervical cancer.

This invention relates to the detection of extracellular papillomavirus DNA in blood plasma or serum from a human or animal. In particular, the invention relates to the detection, identification, evaluation, or monitoring of neoplastic, premalignant or malignant disease associated with a papillomavirus. The invention thereby provides methods for the identification of individuals at risk for, or having, cervical dysplasia, cervical intraepithelial neoplasia, or cervical cancer.

The present invention concerns the use of E6 and/or E7 peptides from human papilloma virus (HPV) to evaluate a cell-mediated response in a patient infected with HPV to determine the prognosis for that patient with respect to the development or recurrence of pre-cancerous or cancerous growths, including cervical intraepithelial neoplasia (CIN).

The invention relates to the fields of genetic engineering and clinical medicine science, and concretely relates to an application of an miRNA marker in the preparation of a cervical intraepithelial neoplasia agent for screening folic acid deficiency populations. The folic acid concentration which is not more than 10 nmol / L is judged as folic acid deficiency, and the miRNA marker comprises the following fourteen miRNAs: miR-10a, miR-375, miR-23a, miR-18a, miR-6774, miR-21, miR-3613, miR-4730, miR-1247, miR-3607, miR-224, miR-30a, miR-30c and miR-196b. A reagent or a kit can be used for inspecting the expression condition of the 14 miRNAs in cervical tissues of folic acid deficiency patients in order to analyze the CIN and cervical cancer suffering risk of like populations.

The invention relates to the field of gene therapy and discloses a fixed-point knockout system for high-risk HPV (human papilloma virus) E6E7 gene, namely targeted cutting of TALENs (transcription activator-like effector nucleases) of HPV E6E7 gene, wherein a TALENs expression vector of the target specific site is designed according to the high-risk HPV E6E7 gene sequence, and the HPV E6E7 gene sequence in the cells are cut in a targeted manner so as to knock out the target gene and induce the apoptosis increase and proliferation inhibition of corresponding subtype cells while the TALENs do not act on the HPV positive or HPV negative cells of other subtypes. By transfecting the TALEN expression vector in a subcutaneous tumor model of HPV positive cervical cancer cells, the growth of subcutaneous tumor can be obviously inhibited, and the tumor weight is reduced. According to the method for targeted knockout of high-risk HPV E6E7 gene using TALEN provided by the invention, the virus oncogene can be efficiently broken on the DNA level so as to cause apoptosis and proliferation inhibition of the HPV infected cells, and the method is of tremendous therapeutic value on HPV infection related diseases and particularly precancerous lesions such as cervical intraepithelial neoplasias.

The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.

The invention discloses a PAP (pokeweed antiviral protein) freeze-dried powder compounding agent as well as a preparation method and an application thereof, in particular to an application in treatment and prevention of HPV (human papillomavirus) virus infection and related diseases. The PAP freeze-dried powder compounding agent comprises PAP freeze-dried powder and a dissolution liquid, wherein components of the PAP freeze-dried powder comprise PAP, phyto-laccasaponin, polysaccharide and cordycepin; and components of the dissolution liquid comprise water, ethanol, phosphate, glycerol, menthol and preservative. The compounding agent prepared by taking PAP as a main component can effectively treat HPV infection, prevent cervical cancer and penis cancer, has a remarkable curative effect on diseases such as CIN (cervical intraepithelial neoplasia), cervical erosion, cervical polyp, cervical hypertrophy and like caused by HPV infection, and has good clinic application prospect.

Physiologically acceptable films for use in the treatment cervical intraepithelial neoplasia are disclosed. The films include a water soluble film-forming polymer such as pullulan, and therapeutically effective amounts of chemexfoliation agents. Devices adapted to introduce these films to the cervix are disclosed, as well as various combinations of devices and films sufficient to comprise a kit to enable treatment of CIN 1, 2, and 3.

The present invention discloses a double-dyeing kit for cervical intraepithelial neoplasia grading assisted diagnosis, and applications thereof, wherein the double-dyeing kit comprises an immunohistochemisty marker first antibody, and the immunohistochemisty marker first antibody is a mixed antibody reagent comprising Stathmin antibody and MCM2 antibody. With the application of the double-dyeing kit in the cervical intraepithelial neoplasia grading assisted diagnosis, the two immunohistochemisty markers are adopted as the mixed antibody so as to increase the sensitivity and the specificity of the CIN grading and accurately identifying the CIN grading; and the readability and the accuracy of the film reading are increased, the detection cost is reduced, and the operation steps are reduced.

Relating to the field of gene therapy, the invention provides a method for knockout of a high-risk human papillomavirus (HPV) E6E7 gene by zinc finger nucleases (ZFNs). According to a high-risk type HPV E6E7 gene sequence, the method designs ZFNs expression vectors of a targeted specific site to targetedly cut the HPVE6E7 gene sequence in cells, thereby knocking out a target gene. In corresponding subtype HPV infected cells, the ZFNs can significantly induce cell apoptosis and proliferation inhibition, and has no effect on other subtype HPV positive cells and HPV negative cells. Transfection of the ZFNs expression vectors in a subcutaneous tumor model of HPV positive cervical cancer cells can obviously inhibit the growth rate of subcutaneous tumors and alleviate tumors. The method for targeted knockout of the high-risk HPV E6E7 gene by ZFNs can efficiently destroy virus oncogenes at the DNA level so as to make HPV infected cells undergo apoptosis and proliferation inhibition, and has enormous treatment value to HPV infection related diseases, especially cervical intraepithelial neoplasias and other precancerous lesions.

The invention discloses an in vitro culture method of cervical intraepithelial neoplasia cells. The in vitro culture method comprises the following steps: step one, taking a small piece of human cervical neoplasia tissue; step two, after digesting and decomposing by a type I collagenase, preparing a cell suspension; step three, utilizing a trypan blue dye exclusion method to judge the cell activity; step four, introducing the cell suspension into a culture bottle containing a low fetal bovine serum culture medium and coated with rat tail collagen, and waiting for the cells to adhere to the wall; and step five, after the cells adhere to the wall, replacing with a serum-free culture medium, purifying the cervical intraepithelial neoplasia cells, replacing the culture liquid weekly for at least two times, and after the cells are fused to 80%-85%, carrying out passage. The CIN cells cultured by the method have high survival rate and high purity, allows the morphology of the cells after passage to have no obvious change compared with that of the primary cells, and is carried with human papillomavirus (HPV); and the success of the CIN cell in vitro culture provides technical support for research on treatment of cervical cancer.

The invention relates to application of tetramethylpyrazine (TMP) to the preparation of a medicine for treating nephropathy. The nephropathy is contrast-induced nephropathy (CIN). The invention has the advantages that: novel use of a Chinese medicine monomer, namely the TMP is provided; the experimental result proves that the TMP can effectively protect the renal functions of cervical intraepithelial neoplasia (CIN) model rats, and has a good effect of preventing and treating CIN; the mechanism research discovers that the TMP can antagonize the apoptosis of a contrast agent, namely iohexol-induced rat renal tubular epithelial cells by inhibiting Caspase3; and the invention provides a novel therapeutic medicine for the CIN, and the novel therapeutic medicine has a good application prospect.

The invention belongs to the technical field of medicines and provides a curcumin-containing pharmaceutical composition containing curcumin, volatile oil of curcuma longa, turmerone, curcumol and borneol. The pharmaceutical composition is definite in component and controllable in quality, can be used for preparing a vaginal administration preparation, a rectal administration preparation or an oral mucosal administration preparation, has favorable treating or preventing effect for HR-HPV (High Risk-Human Pappilomavirus) or LR-HPV (Low Risk-Human Pappilomavirus), cervical diseases (cervical intraepithelial neoplasia and carcinoma of uterine cervix), vulvar cancer, anal carcinoma, rectal cancer, oral cancer, verruca acuminate, verruca vulgaris, verruca plana, verruca plantaris and the like and is suitable for wide clinic application.

The invention relates to human papillomavirus (HPV) oncogene protein as an antiagen for detecting an anti-human-papillomavirus antibody, and the antigen has an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3. The invention also provides an immunodetection kit which comprises the antigen for detecting anti-HPV antibody. The invention also provides application of the antigen used for detecting anti-HPV antibody to detect anti-HPV antibody in human blood or saliva. The antigen used for detecting anti-HPV antibody is capable of detecting an HPV antibody in blood or saliva with high sensitivity and high specificity, and thus the antigen helps to provide basis for doctors to accurately diagnose patient cervical intraepithelial neoplasia and cervical carcinoma transformed from HPV virus oncogene, and the immunodetection kit prepared by employing the antigen is capable of rapidly simply accurately detecting the PHV antibody in blood or saliva and is suitable for large-scale popularization and application.

Immune response modifier (IRM) compounds - imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazolo- quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines - are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.

The present invention provides evidence of post-vaccination immunologic changes in target HPV induced cervical intraepithelial neoplasias that suggest the induction of clinically relevant tissue-localized immune responses, despite modest detectable responses in circulating T lymphocytes. The inventive methods allow for identification of immunological responses to HPV immunotherapies, and means for monitoring responses during clinical trials and treatment regimens.

The invention discloses a free-type HPV18-containing cervical epithelia interior tumor-like lesion cell line and application thereof. A clinic sample from the cell line is 1-2 cm<3> of a cervical epithelia interior tumor-like lesion clinic tissue sample of a HPV18 infected patient, no other treatment is adopted, after in-vitro direct culture, in-vitro stable passage is performed, on the basis of PCR and rolling circle amplification experiments, it is authenticated as a free-type HPV18-containing Chinese woman cervical epithelia interior tumor-like lesion cell named as a cervical epithelia interior tumor-like lesion cell HCINC/HL-017 preserved at CCTCC, and the preservation number is CCTCC NO:C2015124. The cell line can have the application prospect at the aspect of HPV18 virus biology, HPV18 infected cervical cancer tumor biology, and anti-HPV and anti-cervical-cancer drug and vaccine development.